Bayesian Capital Management LP Increases Stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Bayesian Capital Management LP increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 617.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,607 shares of the medical equipment provider’s stock after buying an additional 22,900 shares during the period. Bayesian Capital Management LP’s holdings in Zimmer Biomet were worth $2,810,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Ameriprise Financial Inc. lifted its stake in shares of Zimmer Biomet by 36.2% in the 4th quarter. Ameriprise Financial Inc. now owns 1,359,691 shares of the medical equipment provider’s stock valued at $143,627,000 after purchasing an additional 361,144 shares during the period. Ariel Investments LLC raised its holdings in Zimmer Biomet by 0.3% in the fourth quarter. Ariel Investments LLC now owns 298,101 shares of the medical equipment provider’s stock worth $31,488,000 after purchasing an additional 847 shares in the last quarter. Accredited Wealth Management LLC purchased a new position in Zimmer Biomet during the fourth quarter valued at $36,000. Wahed Invest LLC boosted its holdings in shares of Zimmer Biomet by 6.5% during the 4th quarter. Wahed Invest LLC now owns 5,288 shares of the medical equipment provider’s stock valued at $559,000 after buying an additional 324 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV grew its position in shares of Zimmer Biomet by 86.6% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 17,412 shares of the medical equipment provider’s stock worth $1,839,000 after buying an additional 8,083 shares during the period. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ZBH has been the topic of several research reports. Royal Bank of Canada dropped their price objective on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th. JMP Securities reaffirmed a “market outperform” rating and set a $140.00 price objective on shares of Zimmer Biomet in a research report on Friday, February 7th. Barclays dropped their target price on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a report on Monday, February 10th. Finally, Truist Financial restated a “hold” rating and set a $113.00 price target (down from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Zimmer Biomet presently has an average rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Trading Up 0.3 %

Shares of Zimmer Biomet stock opened at $102.08 on Friday. Zimmer Biomet Holdings, Inc. has a 1-year low of $93.10 and a 1-year high of $122.25. The company’s fifty day simple moving average is $105.53 and its 200-day simple moving average is $106.52. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The stock has a market capitalization of $20.20 billion, a PE ratio of 22.94, a P/E/G ratio of 1.95 and a beta of 0.78.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the prior year, the firm earned $2.20 EPS. As a group, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st were given a $0.24 dividend. The ex-dividend date of this dividend was Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.94%. Zimmer Biomet’s payout ratio is currently 21.57%.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the sale, the senior vice president now owns 8,768 shares in the company, valued at approximately $915,379.20. This represents a 14.13 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.95% of the company’s stock.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.